Safety and Efficacy of Everolimus Use to Preserve Renal Function in Intestinal and Multivisceral Transplantation Patients

Document Type

Article

Publication Date

12-1-2024

Publication Title

Transplantation proceedings

Abstract

BACKGROUND: As calcineurin inhibitors are associated with renal impairment post intestinal transplant, use of everolimus (EVR) may provide renal-sparing benefits.

METHODS: We performed a retrospective analysis focused on EVR use and renal function after intestinal or multivisceral transplant. No prisoners were used in the study. This study is compliant with the Helsinki Congress and the Declaration of Istanbul.

RESULTS: A total of 28 patients, 18 patients who underwent isolated intestinal transplant, and 10 patients who underwent multivisceral transplant, were included in this study. For 13 patients that never received EVR, the average change in estimated glomerular filtration rate (eGFR) compared to baseline at the time of transplant were as follows: 1 year post-transplant = -18.1%; 2 years = -43.7%; 3 years = -44.1; and 5 years = -43.3%. For 15 patients who received EVR after transplant, average duration of EVR therapy was (579.60 ± 784.15) days with 87% of patients ultimately removed from medication due to side effects. In the EVR group, the average change in eGFR compared to baseline were as follows: 1 year post-transplant = -37.5%; 2 years = -43.5%; 3 years = -54.2%; and 5 years = -42.9%. After the initiation of EVR, the average change in eGFR compared to eGFR at time of EVR initiation was as follows: 1 year = +5.9%; 2 years = -1.57%; 3 years = -5.01%; and 5 years = -1.79%.

CONCLUSIONS: This study suggests that EVR can play an important role in preserving renal function in intestinal and multivisceral transplant recipients, but tolerance of EVR is highly variable in this patient population.

Medical Subject Headings

Humans; Everolimus; Retrospective Studies; Intestines; Immunosuppressive Agents; Male; Female; Glomerular Filtration Rate; Adult; Kidney; Middle Aged; Treatment Outcome; Young Adult

PubMed ID

39603963

Volume

56

Issue

10

First Page

2250

Last Page

2254

Find It @ Sladen

Share

COinS